Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials
Open Access
- 28 February 2017
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (7) , 926-935
Abstract
Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular Assessment Study (CANVAS) and the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R). Accruing data for the sodium glucose co‐transporter 2 (SGLT2) inhibitor class has identified questions and opportunities that were not apparent when the trials were designed. Accordingly, a series of modifications have been made to the planned analyses. These updates will ensure that the data from the CANVAS Program will maximize advances in scientific knowledge and patient care. The specification of the analysis strategy prior to knowledge of the trial results, their design by the independent scientific trial Steering Committee, the detailed a priori definition of the analysis plans, and the external review provided by the US Food and Drug Administration all provide maximally efficient and robust utilization of the data. The CANVAS Program should significantly advance our understanding of the effects of canagliflozin, and the broader SGLT2 inhibitor class, on a range of important efficacy and safety outcomes.Keywords
Funding Information
- Janssen Research & Development, LLC
- Janssen Global Services, LLC
This publication has 10 references indexed in Scilit:
- Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trialDiabetes, Obesity and Metabolism, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical ProgramDiabetes Care, 2015
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialDiabetes Therapy, 2015
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 DiabetesDiabetes Care, 2014
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trialAmerican Heart Journal, 2013
- Rosiglitazone: what went wrong?BMJ, 2010
- Medical coding in clinical trialsPerspectives in Clinical Research, 2010